Advanced glycation end products and diabetic complications

Diabetic complications are major cause of morbidity and mortality in patients with diabetes. While the precise pathogenic mechanism(s) underlying conditions such as diabetic retinopathy, diabetic nephropathy and increased risk of atherosclerosis remain ill-defined, it is clear that hyperglycaemia is a primary factor that initiates and promotes complications. Formation of advanced glycation end products (AGEs) correlate with glycaemic control, and these reactive adducts form on DNA, lipids and proteins where they represent pathophysiological modifications that precipitate dysfunction at a cellular and molecular level. Many of these adducts form rapidly during diabetes and promote progression of a raft of diabetes-related complications. Recent evidence also suggests an important interaction with other pathogenic mechanisms activated within the diabetic milieu. This review outlines the nature of AGE formation in biological systems and highlights accumulative evidence that implicates these adducts in diabetic complications. As more therapeutic agents are developed to inhibit AGE formation or limit their pathogenic influence during chronic diabetes, it is becoming clear that these anti-AGE strategies have an important role to play in the treatment of diabetic patients.

[1]  Alan W. Stitt,et al.  A Modulatory Role for Advanced Glycation End-Products (AGEs) in Retinal Microvascular Leukostasis , 2002 .

[2]  M. Steffes,et al.  Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. , 2002, Kidney international.

[3]  T. Metz,et al.  A Post-Amadori Inhibitor Pyridoxamine Also Inhibits Chemical Modification of Proteins by Scavenging Carbonyl Intermediates of Carbohydrate and Lipid Degradation* , 2002, The Journal of Biological Chemistry.

[4]  Hiroshi Yamamoto,et al.  Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. , 2002, Biochemical and biophysical research communications.

[5]  Y. Hattori,et al.  Vascular Smooth Muscle Cell Activation by Glycated Albumin (Amadori Adducts) , 2002, Hypertension.

[6]  D. L. Price,et al.  Chelating Activity of Advanced Glycation End-product Inhibitors* , 2001, The Journal of Biological Chemistry.

[7]  R. Atkins,et al.  Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). , 2001, The Journal of clinical investigation.

[8]  M. Brownlee Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.

[9]  A. Schmidt,et al.  Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: mechanisms and insights into therapeutic modalities. , 2001, Annals of periodontology.

[10]  R. Lewanczuk,et al.  Vascular compliance is reduced in the early stages of type 1 diabetes. , 2001, Diabetes care.

[11]  A. Heidland,et al.  Plasma levels of advanced glycation end products in children with renal disease , 2001, Pediatric Nephrology.

[12]  M. Andrassy,et al.  Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. , 2001, Diabetes.

[13]  H. Founds,et al.  Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links , 2001, Expert opinion on investigational drugs.

[14]  M. Cooper,et al.  Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy , 2001, Diabetologia.

[15]  H. Vlassara The AGE‐receptor in the pathogenesis of diabetic complications , 2001, Diabetes/metabolism research and reviews.

[16]  S. Tesfaye,et al.  Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy , 2001, Diabetologia.

[17]  D. Hsu,et al.  Accelerated diabetic glomerulopathy in galectin‐3/AGE receptor 3 knockout mice , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  J. Mužík,et al.  Polymorphisms 1704G/T and 2184A/G in the RAGE gene are associated with antioxidant status. , 2001, Metabolism: clinical and experimental.

[19]  J. Atkinson,et al.  Aminoguanidine and Aortic Wall Mechanics, Structure, and Composition in Aged Rats , 2001, Hypertension.

[20]  D. Kass,et al.  Improved Arterial Compliance by a Novel Advanced Glycation End-Product Crosslink Breaker , 2001, Circulation.

[21]  T. Shoji,et al.  Femoral artery wall thickness and stiffness in evaluation of peripheral vascular disease in type 2 diabetes mellitus. , 2001, Atherosclerosis.

[22]  S. Takasawa,et al.  Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.

[23]  J. Mužík,et al.  Polymorphisms in the RAGE gene influence susceptibility to diabetes-associated microvascular dermatoses in NIDDM. , 2001, Journal of diabetes and its complications.

[24]  T. Kern,et al.  Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. , 2001, Diabetes.

[25]  P. Grant,et al.  Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. , 2001, Diabetes.

[26]  M. Cooper,et al.  Mechanisms of diabetic vasculopathy: an overview. , 2001, American journal of hypertension.

[27]  C. Esposito,et al.  Long-term exposure to high glucose up-regulates VCAM-induced endothelial cell adhesiveness to PBMC. , 2001, Kidney international.

[28]  H. Parving,et al.  Polymorphism screening of four genes encoding advanced glycation end-product putative receptors. Association study with nephropathy in type 1 diabetic patients. , 2001, Diabetes.

[29]  G. Jerums,et al.  Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery. , 2001, Clinical science.

[30]  K. Uchida,et al.  High concentrations of glucose induce synthesis of argpyrimidine in retinal endothelial cells , 2001, Current eye research.

[31]  A. Schmidt,et al.  The biology of the receptor for advanced glycation end products and its ligands. , 2000, Biochimica et biophysica acta.

[32]  Alan W. Stitt,et al.  Advanced glycation end product receptor interactions on microvascular cells occur within caveolin‐rich membrane domains , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  A. Schmidt,et al.  RAGE: A New Target for the Prevention and Treatment of the Vascular and Inflammatory Complications of Diabetes , 2000, Trends in Endocrinology & Metabolism.

[34]  G. Romeo,et al.  Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. , 2000, Investigative ophthalmology & visual science.

[35]  G. Jerums,et al.  Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. , 2000, Journal of the American Society of Nephrology : JASN.

[36]  M. Kurabayashi,et al.  Circulating Oxidized Low Density Lipoprotein Levels: A Biochemical Risk Marker for Coronary Heart Disease , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[37]  T. Miyata,et al.  Relevance of oxidative and carbonyl stress to long-term uremic complications. , 2000, Kidney international. Supplement.

[38]  A. Jenkins,et al.  Pyridoxamine, an Inhibitor of Advanced Glycation Reactions, Also Inhibits Advanced Lipoxidation Reactions , 2000, The Journal of Biological Chemistry.

[39]  E. Agardh,et al.  Effects of inhibition of glycation and oxidative stress on the development of cataract and retinal vessel abnormalities in diabetic rats. , 2000, Current eye research.

[40]  J. Tooke Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. , 2000, Journal of diabetes and its complications.

[41]  J. Baynes,et al.  Glycoxidation and lipoxidation in atherogenesis. , 2000, Free radical biology & medicine.

[42]  Alan W. Stitt,et al.  Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats. , 2000, Molecular cell biology research communications : MCBRC.

[43]  M. Laakso,et al.  Gly82Ser polymorphism of the receptor of advanced glycation end product gene is not associated with coronary heart disease in Finnish nondiabetic subjects or in patients with type 2 diabetes. , 2000, Diabetes care.

[44]  F. Ziyadeh,et al.  Inhibiting Albumin Glycation Ameliorates Diabetic Nephropathy in the db/db Mouse , 2000, Nephron Experimental Nephrology.

[45]  A. Bender,et al.  Aminoguanidine-mediated Inactivation and Alteration of Neuronal Nitric-oxide Synthase* , 2000, The Journal of Biological Chemistry.

[46]  M. Cooper,et al.  The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation , 2000, Diabetologia.

[47]  M. Obrenovich,et al.  Transition metal-catalyzed oxidation of ascorbate in human cataract extracts: possible role of advanced glycation end products. , 2000, Investigative ophthalmology & visual science.

[48]  M. Ganz,et al.  AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. , 2000, American journal of physiology. Renal physiology.

[49]  A. Cerami,et al.  An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Choudhury,et al.  Advanced glycation end products: a Nephrologist's perspective. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[51]  M. Cooper,et al.  Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[52]  M. Araie,et al.  Advanced glycation end products in diabetic corneas. , 2000, Investigative ophthalmology & visual science.

[53]  S. Cringle,et al.  Continued progression of retinopathy despite spontaneous recovery to normoglycemia in a long-term study of streptozotocin-induced diabetes in rats , 2000, Graefe's Archive for Clinical and Experimental Ophthalmology.

[54]  V. Monnier,et al.  Longitudinal determination of skin collagen glycation and glycoxidation rates predicts early death in C57BL/6NNIA mice , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[55]  H. Parving,et al.  Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. , 1999, Diabetes.

[56]  Paul J Thornalley,et al.  Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. , 1999, The Biochemical journal.

[57]  T. Seiler,et al.  Techniques for stiffening the cornea. , 1999, Journal of refractive surgery.

[58]  M. Cooper,et al.  The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? , 1999, Kidney international.

[59]  E. Vicaut,et al.  Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo. , 1999, Diabetes.

[60]  W. Hung,et al.  Role of the Janus kinase (JAK)/signal transducters and activators of transcription (STAT) cascade in advanced glycation end-product-induced cellular mitogenesis in NRK-49F cells. , 1999, The Biochemical journal.

[61]  R. Nagaraj,et al.  Protein crosslinking by the Maillard reaction: dicarbonyl-derived imidazolium crosslinks in aging and diabetes. , 1999, Archives of biochemistry and biophysics.

[62]  J. Mehlsen,et al.  Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. , 1999, Diabetes care.

[63]  A. Teti,et al.  Effects of advanced glycation end products on cytosolic Ca2+ signaling of cultured human mesangial cells. , 1999, Journal of the American Society of Nephrology : JASN.

[64]  R. G. Paul,et al.  The effect of advanced glycation end-product formation upon cell-matrix interactions. , 1999, The international journal of biochemistry & cell biology.

[65]  H. Vlassara,et al.  Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. , 1999, Diabetes.

[66]  Hiroshi Yamamoto,et al.  Advanced glycation endproducts accelerate calcification in microvascular pericytes. , 1999, Biochemical and biophysical research communications.

[67]  R. Khalifah,et al.  Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. , 1999, Biochemical and biophysical research communications.

[68]  G. Jerums,et al.  A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes , 1999, Diabetologia.

[69]  B. Sonesson,et al.  Increased aortic stiffness in women with type 1 diabetes mellitus is associated with diabetes duration and autonomic nerve function. , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[70]  H. Hammes,et al.  Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Ne-(carboxymethyl) lysine independently of glycohaemoglobin concentrations , 1999, Diabetologia.

[71]  F. Cuccurullo,et al.  Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. , 1999, The Journal of pediatrics.

[72]  S. Genuth,et al.  Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Contro , 1999, Diabetes.

[73]  Alan W. Stitt,et al.  Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells. , 1999, Biochemical and biophysical research communications.

[74]  A. Schmidt,et al.  Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. , 1999, Circulation research.

[75]  M. Lagarde,et al.  In vitro and in vivo alterations of enzymatic glycosylation in diabetes. , 1999, Life sciences.

[76]  H. Sano,et al.  Receptors for proteins modified by advanced glycation endproducts (AGE)—their functional role in atherosclerosis , 1999, Mechanisms of Ageing and Development.

[77]  M. Wolzt,et al.  Ocular blood flow and associated functional deviations in diabetic retinopathy , 1999, Diabetologia.

[78]  Alan W. Stitt,et al.  Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy. , 1998, Investigative ophthalmology & visual science.

[79]  B. Vanhaesebroeck,et al.  A Redox-triggered Ras-Effector Interaction , 1998, The Journal of Biological Chemistry.

[80]  S. Rees,et al.  Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine , 1998, Diabetologia.

[81]  S. Horiuchi,et al.  Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. , 1998, Atherosclerosis.

[82]  R. Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. , 1998, Ophthalmology.

[83]  T. Miyata,et al.  Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? , 1998, Kidney international.

[84]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[85]  Alan W. Stitt,et al.  Increased Levels of Advanced Glycation Endproducts in the Lenses and Blood Vessels of Cigarette Smokers , 1998, Molecular medicine.

[86]  T. Yasuda,et al.  Increased serum levels of advanced glycation end-products and diabetic complications. , 1998, Diabetes research and clinical practice.

[87]  J. Baynes,et al.  Role of the Maillard Reaction in Aging of Tissue Proteins , 1998, The Journal of Biological Chemistry.

[88]  A. Schmidt,et al.  Enhanced interaction of advanced glycation end products with their cellular receptor RAGE: implications for the pathogenesis of accelerated periodontal disease in diabetes. , 1998, Annals of periodontology.

[89]  M. Lagarde,et al.  Modification of enzymatic antioxidants in retinal microvascular cells by glucose or advanced glycation end products. , 1998, Free radical biology & medicine.

[90]  Alan W. Stitt,et al.  Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. , 1998, Diabetes.

[91]  N. Nakamura,et al.  Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells. , 1997, Biochemical and biophysical research communications.

[92]  T. Kita,et al.  Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells. , 1998, Biochemical and biophysical research communications.

[93]  M. Huijberts,et al.  Breakers of advanced glycation end products restore large artery properties in experimental diabetes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[94]  R. Bucala,et al.  Advanced glycation end products increase retinal vascular endothelial growth factor expression. , 1998, The Journal of clinical investigation.

[95]  M. Nangaku,et al.  Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. , 1998, Biochemical and biophysical research communications.

[96]  M Duriez,et al.  Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[97]  J. C. Sánchez-Thorin The cornea in diabetes mellitus. , 1998, International ophthalmology clinics.

[98]  K. Matsumoto,et al.  Immunochemical evidence for increased formation of advanced glycation end products and inhibition by aminoguanidine in diabetic rat lenses. , 1997, Biochemical and biophysical research communications.

[99]  R. Bucala,et al.  Tobacco smoke is a source of toxic reactive glycation products. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[100]  A. Amos,et al.  The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010 , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[101]  G. Romeo,et al.  Upregulation of Mesangial Growth Factor and Extracellular Matrix Synthesis by Advanced Glycation End Products Via a Receptor-Mediated Mechanism , 1997, Diabetes.

[102]  S. Yagihashi,et al.  Localization in human diabetic peripheral nerve of Nɛ-carboxymethyllysine-protein adducts, an advanced glycation endproduct , 1997, Diabetologia.

[103]  G. Jerums,et al.  DIABETIC VASCULAR COMPLICATIONS , 1997, Clinical and experimental pharmacology & physiology.

[104]  Alan W. Stitt,et al.  Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs , 1997, Molecular medicine.

[105]  A. Schmidt,et al.  Activation of the Receptor for Advanced Glycation End Products Triggers a p21 ras -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress* , 1997, The Journal of Biological Chemistry.

[106]  A. Heidland,et al.  Advanced glycation endproducts stimulate the MAP‐kinase pathway in tubulus cell line LLC‐PK1 , 1997, FEBS letters.

[107]  R. Bucala,et al.  Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[108]  J. Baynes,et al.  N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. , 1997, The Biochemical journal.

[109]  M. Donaghy,et al.  Nonenzymatic glycation of peripheral and central nervous system proteins in experimental diabetes mellitus , 1997, Muscle & nerve.

[110]  Z. Makita,et al.  Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation , 1997, Diabetes.

[111]  Alan W. Stitt,et al.  Atherogenesis and Advanced Glycation: Promotion, Progression, and Prevention a , 1997, Annals of the New York Academy of Sciences.

[112]  Hiroshi Yamamoto,et al.  Advanced Glycation End Products-driven Angiogenesis in Vitro , 1997, The Journal of Biological Chemistry.

[113]  Alan W. Stitt,et al.  Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. , 1997, The American journal of pathology.

[114]  H. Oxlund,et al.  Changes in biomechanical properties, composition of collagen and elastin, and advanced glycation endproducts of the rat aorta in relation to age. , 1996, Atherosclerosis.

[115]  G. Crepaldi,et al.  Patterns of renal injury in NIDDM patients with microalbuminuria , 1996, Diabetologia.

[116]  P. Flatt,et al.  Glycation of Insulin in the Islets of Langerhans of Normal and Diabetic Animals , 1996, Diabetes.

[117]  E. Howard,et al.  Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. , 1996, Experimental cell research.

[118]  Alan W. Stitt,et al.  Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[119]  N. Nakamura,et al.  Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo. , 1996, Biochemical and biophysical research communications.

[120]  H. Hammes,et al.  Modification of vitronectin by advanced glycation alters functional properties in vitro and in the diabetic retina. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[121]  G. Jerums,et al.  Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. , 1996, Kidney international.

[122]  J. Bernhagen,et al.  An agent cleaving glucose-derived protein crosslinks in vitro and in vivo , 1996, Nature.

[123]  H. Sano,et al.  Advanced Glycation End Products and Their Recognition by Macrophage and Macrophage-Derived Cells , 1996, Diabetes.

[124]  T. Kern,et al.  Capillary lesions develop in retina rather than cerebral cortex in diabetes and experimental galactosemia. , 1996, Archives of ophthalmology.

[125]  A. Gugliucci,et al.  Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells , 1996, Diabetologia.

[126]  J. Baynes,et al.  Pathways of formation of glycoxidation products during glycation of collagen. , 1995, Biochemistry.

[127]  Alan W. Stitt,et al.  Increased endocytosis in retinal vascular endothelial cells grown in high glucose medium is modulated by inhibitors of nonenzymatic glycosylation , 1995, Diabetologia.

[128]  Yong Ming Li,et al.  Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation–modified proteins to a conserved motif , 1995, Nature Medicine.

[129]  S. Kuwajima,et al.  Advanced glycation endproducts and diabetic nephropathy. , 1995, Journal of diabetes and its complications.

[130]  A. Schmidt,et al.  Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. , 1995, The Journal of clinical investigation.

[131]  H. Hammes,et al.  Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model , 1995, Diabetologia.

[132]  E M Kohner,et al.  Role of Blood Flow and Impaired Autoregulation in the Pathogenesis of Diabetic Retinopathy , 1995, Diabetes.

[133]  A. Gugliucci,et al.  Reaction of advanced glycation endproducts with renal tissue from normal and streptozotocin-induced diabetic rats: an ultrastructural study using colloidal gold cytochemistry. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[134]  R. Bucala,et al.  Identification of the Major Site of Apolipoprotein B Modification by Advanced Glycosylation End Products Blocking Uptake by the Low Density Lipoprotein Receptor (*) , 1995, The Journal of Biological Chemistry.

[135]  G. Jerums,et al.  The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat , 1995, Diabetologia.

[136]  Alan W. Stitt,et al.  Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. , 1995, The British journal of ophthalmology.

[137]  Alan W. Stitt,et al.  Retinal vascular endothelial cell endocytosis increases in early diabetes. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[138]  H. Hammes,et al.  Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats , 1995, Diabetologia.

[139]  Yong Ming Li,et al.  Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[140]  A. Schmidt,et al.  Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[141]  G. Striker,et al.  Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[142]  S. Grundy,et al.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[143]  J. Ávila,et al.  Analysis of microtubule-associated protein tau glycation in paired helical filaments. , 1994, The Journal of biological chemistry.

[144]  M. Brownlee,et al.  Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. , 1994, The Journal of clinical investigation.

[145]  K. Meek,et al.  The inhibition of sugar-induced structural alterations in collagen by aspirin and other compounds. , 1994, Biochemical and biophysical research communications.

[146]  Alan W. Stitt,et al.  Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments. , 1994, The British journal of ophthalmology.

[147]  Alan W. Stitt,et al.  Selective loss of vascular smooth muscle cells in the retinal microcirculation of diabetic dogs. , 1994, The British journal of ophthalmology.

[148]  M. Cotter,et al.  Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats , 1992, Diabetologia.

[149]  T. Orchard,et al.  Diabetes Mellitus and Macrovascular Complications: An epidemiological perspective , 1992, Diabetes Care.

[150]  V. Monnier,et al.  Immunohistochemical detection of advanced glycosylation end products in diabetic tissues using monoclonal antibody to pyrraline. , 1992, The Journal of clinical investigation.

[151]  R. S. Wall,et al.  Ageing of the human corneal stroma: structural and biochemical changes. , 1992, Biochimica et biophysica acta.

[152]  H. Hammes,et al.  Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[153]  Paul J Thornalley The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. , 1990, The Biochemical journal.

[154]  M. Zemel,et al.  Hypertension and diabetes. , 1988, The Medical clinics of North America.

[155]  W. Knowler,et al.  Predisposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. , 1988, The New England journal of medicine.

[156]  V. Monnier,et al.  Detection of D-glucose-derived pyrrole compounds during Maillard reaction under physiological conditions. , 1987, Carbohydrate research.

[157]  T. Kern,et al.  Progression of Incipient Diabetic Retinopathy During Good Glycemic Control , 1987, Diabetes.

[158]  R. Østerby Structural changes in the diabetic kidney , 1986 .

[159]  A. Cerami,et al.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.

[160]  J. Baynes,et al.  Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. , 1986, The Journal of biological chemistry.

[161]  A. Cerami,et al.  Nonenzymatic Glycosylation Products on Collagen Covalently Trap Low-Density Lipoprotein , 1985, Diabetes.

[162]  D. Archer,et al.  A morphologic and autoradiographic study of cell death and regeneration in the retinal microvasculature of normal and diabetic rats. , 1985, American journal of ophthalmology.

[163]  S. Pongor,et al.  Covalent attachment of soluble proteins by nonenzymatically glycosylated collagen. Role in the in situ formation of immune complexes , 1983, The Journal of experimental medicine.

[164]  P. Johnson,et al.  Thickened cerebral cortical capillary basement membranes in diabetics. , 1982, Archives of pathology & laboratory medicine.

[165]  M. Brownlee,et al.  Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats , 2004, Diabetologia.

[166]  U. Junker,et al.  Basement membrane of hypothalamus and cortex capillaries from normotensive and spontaneously hypertensive rats with streptozotocin-induced diabetes , 2004, Acta Neuropathologica.

[167]  A. Heidland,et al.  Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. , 2002, Journal of hepatology.

[168]  A. Cerami,et al.  Protein glycation, diabetes, and aging. , 2001, Recent progress in hormone research.

[169]  G. Jerums,et al.  Renoprotective effects of a novel inhibitor of advanced glycation , 2001, Diabetologia.

[170]  T. Gardner,et al.  Molecular mechanisms of vascular permeability in diabetic retinopathy. , 1999, Seminars in ophthalmology.

[171]  G. Jerums,et al.  Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. , 1998, Atherosclerosis.

[172]  H. Hammes,et al.  The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster , 1998, Diabetologia.

[173]  S. Yagihashi,et al.  Localization in human diabetic peripheral nerve of N(epsilon)-carboxymethyllysine-protein adducts, an advanced glycation endproduct. , 1997, Diabetologia.

[174]  E. Kohner,et al.  Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy , 1997, Diabetologia.

[175]  M. Lagarde,et al.  Growth modulation of retinal microvascular cells by early and advanced glycation products. , 1997, Diabetes research and clinical practice.

[176]  T. Kern,et al.  Vascular lesions in diabetes are distributed non-uniformly within the retina. , 1995, Experimental eye research.

[177]  T. Kodama,et al.  Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. , 1995, The American journal of pathology.

[178]  H. Hammes,et al.  Erratum: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy (Proc. Natl. Acad. Sci. USA (December 15, 1991) 88:24 (11555-11558)) , 1992 .

[179]  R. Osterby Structural changes in the diabetic kidney. , 1986, Clinics in endocrinology and metabolism.

[180]  R. Bucala,et al.  Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. , 1984, Proceedings of the National Academy of Sciences of the United States of America.